Journal
LEUKEMIA & LYMPHOMA
Volume 50, Issue 2, Pages 247-253Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190802688152
Keywords
Essential thrombocythemia; JAK2V617F mutation; long-term outcome
Categories
Funding
- University of Bologna
Ask authors/readers for more resources
The JAK2V617F mutation occurs in 50% of patients with essential thrombocythemia (ET). We investigated the correlation between the JAK2V617F mutation and clinical and laboratory characteristics, thrombohemorrhagic risk and incidence of disease evolution in 275 patients with ET followed for a median follow-up of 7 years. JAK2V617F mutation was detected in 175 patients (64%), of whom 173 were heterozygous. Patients with the mutation were older and displayed higher hemoglobin and hematocrit levels, but lower platelet count. Cytotoxic treatment requirement was similar in the two groups, but patients with the mutation showed better responses. Incidence of thrombosis and disease evolution was comparable. JAK2 mutational status assessment was valuable to distinguish two populations of patients with ET, showing distinctive hematologic and clinical features.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available